w66最给利老牌

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2024

VOLUNTARY ANNOUNCEMENT - ESG PERFORMANCE RECOGNISED BY S&P GLOBAL AND FTSE RUSSELL

VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR CATEGORY 1 INNVOATIVE DRUG CULMERCICLIB CAPSULE "CULMERCICLIB (TQB3616)"

VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS ON PHASE III STUDY OF ANLOTINIB HYDROCHLORIDE CAPSULE IN COMBINATION WITH CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA

VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR CATEGORY 1 INNVOATIVE DRUG ROVADICITINIB TABLET "ROVADICITINIB (TQ05105)"

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2024

VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF "LIRAGLUTIDE INJECTION"

VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY CHIA TAI TIANQING UNDER THE SHARE INCENTIVE SCHEME